EHF (ETS homologous factor) is a transcription factor that functions primarily as a regulator of epithelial cell differentiation and proliferation. EHF binds to DNA sequences containing the GGAA consensus core and modulates RNA polymerase II-dependent transcription 1. In mammary tissue, EHF is essential for alveolar lineage differentiation during lactation; loss of EHF impairs lobuloalveolar development, reduces milk gene expression, and increases progenitor cell accumulation 2. In pancreatic cancer, EHF functions as a tumor suppressor through multiple mechanisms. EHF suppresses cancer stemness by transcriptionally inhibiting CXCR4 and stem cell markers (Sox9, Sox2, Oct4, Nanog), thereby reducing sensitivity to cancer stem cell-supportive niches 3. Additionally, EHF negatively regulates CXCL1 transcription; loss of EHF increases CXCL1-mediated CXCR2+ neutrophil recruitment, promoting chemotherapy and immunotherapy resistance 4. Low EHF expression associates with increased tumor grade and poor prognosis in breast cancer subtypes 2. These findings establish EHF as a bona fide tumor suppressor in epithelial cancers, with therapeutic potential through pharmacological restoration of EHF expression or downstream pathway inhibition.